Results in Teens

Annie,
Real patient. Individual
results may vary.

See What's Possible. Feel What's Possible.

DUPIXENT was studied in a 16-week clinical trial with 251 patients* ages 12-17 with
moderate-to-severe eczema not adequately controlled with topical prescription treatments.

Results from a 16-week clinical trial of teens ages 12-17 with DUPIXENT when used alone compared to teens not taking DUPIXENT

12XSaw
Clearer Skin
12X more teens saw clearer skin
(24% vs 2% in those not taking
DUPIXENT)
75%Skin
Improvement
75% skin improvement in nearly half of
teens, and some even saw 90%
improvement
(42% vs 8% in those not
taking DUPIXENT and 23% vs 2% not
taking DUPIXENT, respectively)
7XHad Significant
Itch Reduction
7X more teens experienced itch relief
(37% vs 5% in those not taking
DUPIXENT)

The safety results of DUPIXENT observed in adolescents were consistent with what was seen in adults
with atopic dermatitis. The most common side effects include injection site reactions, eye and eyelid
inflammation, including redness, swelling, and itching, and cold sores in your mouth or on your lips.


*Patients who weighed ≥60 kg received DUPIXENT 300 mg every two weeks after an initial dose of 600 mg (two 300 mg injections),
and patients who weighed ≤60 kg received DUPIXENT 200 mg every two weeks after an initial dose of 400 mg (two 200 mg injections)


What You Should Know About the Patients in This Study:

46%
had moderate atopic dermatitis
54%
had severe atopic dermatitis
≈15 years
Average age
≈57%
Average body surface area involvement
92%
Had at least one other allergic condition

GET DOWN TO THE DETAILS

Expand the boxes below to see more detailed results from the clinical study with patients ages 12-17.

Results at 16 weeks when DUPIXENT was used alone compared to
patients ages 12-17 not taking DUPIXENT

DUPIXENT 200 mg (<60 kg) or 300 mg (≥60 kg) every 2 weeks Not taking DUPIXENT

24% of patients ages 12-17 had clear or almost clear skin compared to 2% not taking DUPIXENT

42% of patients ages 12-17 showed a 75% improvement in their skin compared to 8% not taking DUPIXENT

23% of patients ages 12-17 showed a 90% improvement in their skin compared to 2% not taking DUPIXENT

Patients ages 12-17 experienced a significant itch reduction as defined within the clinical trial

DUPIXENT 200 mg (<60 kg) or 300 mg (≥60 kg) every 2 weeks Not taking DUPIXENT

37% of patients ages 12-17 had significant itch reduction at 16 weeks when DUPIXENT was used alone compared to 5% not taking DUPIXENT

We were a little skeptical at first. Then, we noticed her skin clearing and improving over time. It was such a relief to find something that works for her.

- Yetunde, caregiver of Ore (pictured ),
teen patient taking DUPIXENT

Individual results may vary.

Yetunde and Ore’s Story
Find a Specialist Who
Treats Eczema

Use this Healthgrades™ tool to easily find nearby specialists with experience in treating children, teens, and adults with uncontrolled moderate-to-severe eczema (atopic dermatitis).

Are you sure you want to leave?
Please note: By clicking on this link, you will be leaving this Sanofi-hosted US website and going to another, entirely independent website. Sanofi US and Regeneron provide these links as a service to its website visitors and users; however, they take no responsibility for the information on any website but their own.
Have an Effective Conversation
With Your Doctor

Our goal is for your child or teen to get the most out of their visit to the doctor. Download the discussion guide for tips on how to have a productive conversation.


Get the Child Doctor Discussion Guide

Download